HNSCC ID-3Translational therapy monitoring of locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) with 18F-FDG PET-CT and liquid biopsy under immunotherapy

Recruiting

• Conditions: C00; C01; C02; C03; C04; C05; C06; C07; C08; C09

• Registration Number: DRKS00025330
• Lead Sponsor: Klinikum der Universität München, Campus Großhadern

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-08-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

First-line immunotherapy
- locally advanced / metastatic disease
- target lesions in PET/CT
- life expectancy > 6 months

Exclusion Criteria

- autoimmune disease
- local resection or treatment of HNSCC
- treatment with steroids or immunosuppressive medication

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression Free Survival

Secondary Outcome Measures

Name	Time	Method
Overall Survival